Seegene, Inc. (096530.KQ)
| Previous Close | 22,150.00 |
| Open | 22,200.00 |
| Bid | 22,350.00 x 0 |
| Ask | 22,400.00 x 0 |
| Day's Range | 22,100.00 - 22,550.00 |
| 52 Week Range | 19,040.00 - 30,600.00 |
| Volume | |
| Avg. Volume | 322,221 |
| Market Cap | 1.031T |
| Beta (5Y Monthly) | -1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
Seegene and UK Health Security Agency convene a summit to collectively realize "a World Free from All Diseases"
Seegene Inc., a leading South Korean company providing a total solution for PCR molecular diagnostics, announced today that Prof. Dame Jenny Harries, Chief Executive of the UK Health Security Agency (UKHSA), visited its headquarters located in Seoul Korea, on March 27.
- PR Newswire
Seegene and Springer Nature Announce Awardees for the Open Innovation Program
Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, and Springer Nature, a world-leading provider of services to the research community, unveiled the final list of participants for the diagnostic reagent development project on March 15, 2024(GMT), through the online platform of the Open Innovation Program (https://openinnovation.seegene.com/open-innovation/2023-2024-announcements/).
- PR Newswire
Seegene Announces Collaboration with Microsoft to Realize 'a World Free from All Diseases'
Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, announced its selection of Microsoft as a technology partner for its SG OneSystemTM business in London, UK, on January 23 to realize 'a world free from all diseases.'
